At what enterprise value was SOMALOGIC acquired in 2026?

You can find the full valuation details of SOMALOGIC on mynth capital. The transaction's Enterprise Value is estimated to be in the range of 300M - 700M USD. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Industry & Manufacturing industry currently tracks an average EBITDA multiple of 10.9x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of SOMALOGIC when it was acquired by ILLUMINA?

The exact EV/EBITDA multiple for SOMALOGIC is available on mynth capital. For comparison, the Industry & Manufacturing sector currently shows an average EBITDA multiple of 10.9x. Join our community for free to access full valuation data and industry trends.

When was SOMALOGIC acquired by ILLUMINA?

SOMALOGIC was acquired by ILLUMINA in 2026.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the SOMALOGIC acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the SOMALOGIC deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://investors.standardbio.com/news-releases/news-release-details/standard-biotools-completes-sale-somalogic-illumina

← DATABASE

Home Database Industry & ManufacturingSOMALOGIC

01/2026

SOMALOGIC acquired by ILLUMINA

UNITED STATES Industrial Equipment / Special Machinery / Lab & Scientific Equipment EV 300M - 700M USD

Context

The acquisition of the SomaLogic business unit by Illumina marks a significant strategic maneuver designed to consolidate leadership in the emerging multi-omics landscape. The strategic rationale for this transaction centers on the integration of the target’s high-plex proteomics platform with the group’s world-leading sequencing technology. This fusion effectively creates a unified ecosystem capable of correlating genomic sequences with real-time protein expressions, providing researchers with an unprecedented "end-to-end" view of biological systems. For the seller, the operation allows for a definitive structural refocusing on its core microfluidics and mass cytometry divisions, while establishing a formidable capital position for future inorganic growth. The maneuver optimizes the group’s financial profile by offloading the intensive capital requirements of the proteomics services division and retaining a long-term royalty interest in future product developments. For the acquirer, the integration facilitates the scaling of proteomic-informed genomics, sharpening its focus on high-value applications in pharmaceutical R&D and clinical monitoring. Ultimately, the partnership solidifies the combined entity’s standing as a primary provider of multi-omic innovation, bridging the gap between sophisticated laboratory-scale diagnostics and industrialized scientific discovery standards.

As a reminder, the company was previously acquired by Standard Biotools in 2024 as part of its expansion strategy.

SOMALOGIC, which reported an EBITDA margin of LOGIN in 2026, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Industry & Manufacturing sector (10.9x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Industry & Manufacturing market trends

Target

SomaLogic operates as a premier technology organization dedicated to the engineering and commercialization of next-generation proteomics tools. The entity’s business model is centered on a proprietary framework of protein measurement utilizing SOMAmer (Slow Off-rate Modified Aptamer) reagents, which allow for the high-plex, high-sensitivity detection of thousands of proteins from a single sample. Its value proposition is anchored in technical operational depth, providing researchers with actionable insights into the proteome to bridge the gap between genomic potential and phenotypic reality. Strategically, the firm focuses on the deployment of its SomaScan platform through a network of authorized sites and internal assay services, targeting the global biopharmaceutical and academic research markets. By maintaining a specialized focus on standardized, repeatable protein data, the organization ensures a mission-critical role in the structural advancement of precision medicine and drug discovery. The entity prioritizes technical innovation and industrialized analytical standards to facilitate the structural efficiency of biomarker identification.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (USD)

Year

Rev

EBITDA

EBIT

2026

2025

Other operations with SOMALOGIC

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
01/2024	STANDARD BIOTOOLS	SOMALOGIC	UNITED STATES	Industrial Equipment	The merger between Standard BioTools and SomaLogic creates a diversified and scaled leader in the life sciences tools industry. The strategic rationale for this transaction centers on a "multi-omic integration" play, merging the target's technical operational depth in proteomics with the group's established mass cytometry and microfluidics platforms. This fusion effectively creates a specialized powerhouse capable of delivering clinical research insights with high throughput and data quality across approximately 50 countries. This operation allows the group to execute a definitive structural expansion of its commercial reach, leveraging substantial cross-selling opportunities between the target’s biopharmaceutical research footprint and the group’s academic research settings. By incorporating the target's innovative proteomic tools, the organization can now provide a more robust and integrated solution set for translational and clinical research. The maneuver optimizes the group's financial profile through the realization of significant cost synergies while utilizing a formidable capital structure to self-fund future growth initiatives. Ultimately, the partnership solidifies the group’s standing as a primary enabler of multi-omic innovation, bridging the gap between sophisticated laboratory-scale research and industrialized pharmaceutical development standards.

REFERENCES

Valuation range: EV 300M - 700M USD

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of SOMALOGIC by ILLUMINA are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: somalogic